The Pharma Data

JUNE 17, 2022

At Sandoz, we are constantly looking for ways to meet the changing needs of patients and health care providers,” said Florian Bieber, Global Head Biopharmaceuticals Development, Sandoz. “By About adalimumab Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a).

Medicine 52

Medicine Generic Pharmaceutical FDA Approval Packaging 52

Pharmaceutical Technology

DECEMBER 22, 2022

AstraZeneca and Daiichi Sankyo win the Business Expansion award this year as their collaboration bears more fruit in terms of new approvals. The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects. Innovation.

Insulin 130

Insulin Production Development Genetics 130

The Pharma Data

APRIL 4, 2023

It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development. About adalimumab Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a). Our ambition is to be the world’s leading and most valued generics company.

Medicine 40

Medicine Generic Pharmaceutical FDA Approval Marketing 40

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98